Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
362 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05523960 | Mechanical Bowel Preparation Versus no Bowel Preparation for Esophageal Cancer Surgery | completed | N/A | 652 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT06389422 | Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER |
| 1 |
| Apr 29, 2024 |
| clinicaltrials |
| NCT06371586 | Neo-Sequence 2:NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC | recruiting | Phase 2 | 67 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05540145 | Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma | completed | — | 70 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06354036 | Transhiatal Tunnel Valvuloplasty for Reconstruction Following the Laparoscopic Proximal Gastrectomy | unknown | N/A | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06350370 | Short-term and Long-term Outcomes of Colorectal Cancer Treated With Natural Orifice Specimen Extraction Surgery : a National Registry-based Study | recruiting | N/A | 8,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT06345287 | Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC | recruiting | Phase 2 | 133 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06345300 | NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study | unknown | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06202001 | Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients | recruiting | Phase 1 / Phase 2 | 70 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05749302 | Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins | unknown | Phase 2 / Phase 3 | 500 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT04543695 | A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer | unknown | Phase 2 | 255 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT05283616 | Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer | completed | Phase 3 | 122 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06314542 | Quantitative Evaluation of the Impact of Relaxing Eligibility Criteria for Lung Cancer Based on Real-world Data | unknown | — | 50,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT06293612 | Constructing a Multimodal Imaging System to Predict the Risk of Heterochronous Metastasis of Rectal Cancer(MIS-MRC) | completed | — | 302 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06287320 | The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer | unknown | — | 200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT06289023 | HA-WBRT-SIB for Brain Metastasis of Lung Cancer | completed | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT06277180 | 68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC | recruiting | N/A | 50 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06255912 | Clinical Trial for Advanced or Metastatic Pancreatic Cancer | not yet recruiting | Phase 2 | 26 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 23, 2024 | clinicaltrials |
| NCT06255197 | Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers | recruiting | — | 60,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06245824 | Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial | not yet recruiting | Phase 4 | 51 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05385926 | Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 34 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT06229067 | Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 182 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jan 29, 2024 | clinicaltrials |
| NCT06202014 | Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC | unknown | Phase 2 | 43 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT06205472 | Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC. | recruiting | Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT03535259 | Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma(SIRAHCC) | completed | Phase 2 | 86 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT05021250 | SBRT With DIBH for HCC After TACE and Lipiodol Marking | unknown | N/A | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06198907 | Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)(JACKPOT33) | not yet recruiting | Phase 2 | 69 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06185400 | RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations | not yet recruiting | Phase 2 | 108 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Dec 29, 2023 | clinicaltrials |
| NCT06170697 | Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma | unknown | Phase 2 | 46 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 20, 2023 | clinicaltrials |
| NCT06170710 | Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC | recruiting | Phase 2 | 173 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 14, 2023 | clinicaltrials |
| NCT06156761 | Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer | unknown | N/A | 24 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT06149533 | Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients(Thrombosis) | not yet recruiting | Phase 3 | 366 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT02988921 | MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy | recruiting | N/A | 300 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT06135571 | Study on the No.253 Lymph Node Metastasis Patterns in Left-Sided Colon and Rectal Cancer | unknown | — | 3,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06115837 | Prognosis Stratification for pT4bN0M0 Colorectal Cancer Following Multivisceral Resection | completed | — | 172 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT06114420 | Surgical Treatment and Molecular Marker Exploration of Locally Recurrent Colorectal Cancer | unknown | — | 500 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06084767 | 68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer | unknown | N/A | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06087068 | Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma | recruiting | Phase 2 | 140 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06082180 | A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer | recruiting | Phase 3 | 1,199 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06082557 | A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 62 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Oct 13, 2023 | clinicaltrials |
| NCT06082570 | A Study to Observe and Evaluate the Safety and Efficacy of c610 Injection for Treatment of Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 62 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Oct 13, 2023 | clinicaltrials |
| NCT05777824 | Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy(HN) | recruiting | Phase 2 | 84 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT06074484 | A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer | unknown | Phase 2 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06033794 | Applications of Fluorescence Imaging Guided Lymph Node Dissection and Fluorescence Angiography of Inferior Mesenteric Artery Assisted Left Colic Artery Preservation | unknown | N/A | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06034964 | Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC | unknown | — | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05730595 | Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer(FLORA-01) | not yet recruiting | N/A | 550 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05986227 | The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II):(SCORPIO) | unknown | Phase 1 / Phase 2 | 126 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 14, 2023 | clinicaltrials |
| NCT05983094 | Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer | not yet recruiting | Phase 2 | 181 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05983107 | Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer | recruiting | Phase 2 | 102 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05974007 | Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC(NeoR-World) | unknown | — | 1,500 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 3, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials